Vanda Pharmaceuticals Inc. VNDA announced that the FDA issued a complete response letter (CRL) to its new drug application ...

The end of the trading week likely can't come fast enough for Vanda Pharmaceuticals (NASDAQ: VNDA). The commercial-stage ...

Vanda pharmeucitals received a rejection for its drug tradipitant, causing the company management to criticize the FDA.

A D.C. drugmaker has been dealt a major setback in its long-running bid to bring its treatment for a chronic gastrointestinal ...

Vanda Pharmaceuticals Inc. (VNDA) stock saw a decline, ending the day at $4.94 which represents a decrease of $-0.14 or -2.76% from the prior close of $5.08. The stock opened at $5.12 and touched a ...

Jamie Dimon warns geopolitical tensions, especially the Ukraine war and Middle East conflicts, are the biggest risks to ...

(RTTNews) - Vanda Pharmaceuticals (VNDA) said, on September 18, the FDA declined to approve New Drug Application of tradipitant for the treatment of symptoms in gastroparesis, providing the company ...

The U.S. Food and Drug Administration has declined to approve Vanda Pharmaceuticals' drug to treat stomach paralysis symptoms ...

Vanda Pharmaceuticals’ shares were down more than 10% at $4.45 pre-market today, as the company provided an unfavorable ...

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today provided an update on its tradipitant development program.

Vanda Pharmaceuticals Inc. (NASDAQ: VNDA)周三宣布,美国食品和药物管理局(FDA)未批准其新药申请(NDA),该申请旨在使用tradipitant治疗胃轻瘫症状。FDA通过完整回复信(CRL)向Vanda传达了这一决定。 胃轻瘫是一种慢性疾病,会阻碍胃部正常排空,导致恶心和呕吐等严重症状。尽管有两项安慰剂对照研究支持tradipitant的有效性,但FDA要 ...

WASHINGTON, Sept. 4, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the H.C. Wainwright Global Investment Conference in New ...